Results filed 29 October 2026 · Market cap ₹1,29,972 crore · PE 97
GrowthGuidance maintainedTranscript read
Revenue
+33.4%
on a year ago
EBITDA
+86.1%
on a year ago
Profit to shareholders
+126.4%
on a year ago
EBITDA margin
34.0%
+2.5 pts on last quarter
Laurus Labs reported strong Q2 FY27 revenue growth of 33% YoY to INR 2,206 cr and EBITDA margin expansion to 34.5%, propelled by an 86% YoY jump in small molecule CDMO sales. The company announced strategic expansions into oligonucleotides and peptide resins via majority acquisitions of Galenvs Sciences and SI & C Resins, alongside operationalizing a >16,000 L peptide synthesis block. However, H1 free cash flow turned slightly negative due to high capex of INR 864 cr and working capital absorption, with Bio segment revenue contracting 38% YoY.
Laurus Labs Limited, Q2 FY27₹ crore, consolidated
Q2 FY27
Q1 FY27
vs previous quarter
Q2 FY26
vs a year ago
Revenue
2,206
2,026
+8.9%
1,653
+33.4%
Operating profit (EBIT)
623
514
+21.1%
283
+120.3%
Operating margin
28.2%
25.4%
+285 bps
17.1%
+1113 bps
Other income
13.01
9.18
+41.7%
26.96
−51.7%
Exceptional items
0
0
–
0
–
Profit before exceptional items and tax
592
481
+22.9%
270
+119.4%
Profit to shareholders
441
368
+20.1%
195
+126.4%
Share of joint ventures' and associates' profit
−0.55
0.08
n.m.
0.74
n.m.
Earnings per share (₹)
8.17
6.81
+20.0%
3.61
+126.3%
Source: Laurus Labs Limited’s filing to NSE, 29 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
What stood out
Significant margin expansion driven by small molecule CDMO ramp-up and operational leverageSourceEBITDA margins expanded by 850 bps YoY to 34.5% (EBITDA of INR 762 cr, up 78% YoY), driven by small molecule CDMO sales surging 86% YoY to INR 875 cr (Presentation, slide 15 and 16; Transcript, page 4, Krishna Chava).
Major strategic push into TIDES (peptides and oligonucleotides) through internal scale-up and two acquisitionsSourceCommissioned commercial-scale peptide block with >16,000 L SPPS capacity and announced acquisitions of 60% in Galenvs Sciences for USD 3.75 mn and 52% in SI & C Resins (Press Release, pages 2, 5, 8; Presentation, slides 6, 7).
Heavy ongoing capital expenditure program of INR 3,000 cr across FY27-FY28 with negative H1 free cash flowSourceH1 capex stood at INR 864 cr (20% of revenue) resulting in negative free cash flow, with annual capex guided at ~INR 1,500 cr per year (Presentation, slides 6, 9; Transcript, pages 14, 19, V.V. Ravi Kumar and Dr. Satyanarayana Chava).
Guidance
Metric
Guidance
Period
Gross MarginSourceTranscript, page 12, Dr. Satyanarayana Chava: 'we were able to maintain 60-plus percentage of gross margin... I think we still stick to our guidance.'
Comfortable maintaining over 60%
FY27
EBITDA MarginSourceTranscript, page 12, Dr. Satyanarayana Chava: 'and over 30% EBITDA. I think we still stick to our guidance.'
Comfortable maintaining over 30%
FY27
CapexSourcePresentation, slide 9; Transcript, page 14, Dr. Satyanarayana Chava: 'INR3,000 crores capex for '27, '28 is the right number... around INR1,500 crores per year capital expenditure'.
>INR 3,000 cr across FY27 and FY28 (~INR 1,500 cr per year)
FY27 - FY28
Maintained annual targets of >60% gross margin and >30% EBITDA margin, while reiterating INR 3,000 cr capex across FY27-FY28.
Tailwinds
Robust growth in Small Molecule CDMOSourceSmall Molecule CDMO revenues reached INR 875 cr in Q2 FY27, up 86% YoY, driven by execution of late-stage programs, commercial API supplies, and new asset ramp-ups (Presentation, slide 20; Transcript, page 4, Krishna Chava).
Operational leverage expanding EBITDA marginSourceEBITDA margin reached 34.5% (up 850 bps YoY) on higher absorption and favorable divisional mix, with CDMO contributing 41% of divisional sales (Presentation, slide 16; Transcript, page 6, V.V. Ravi Kumar).
Consistent growth and pricing stability in Affordable Medicines Formulations (FDF)SourceAffordable Medicines FDF revenue rose 31% YoY to INR 677 cr in Q2 FY27 due to expanded order books and stable pricing in ARV and developed market portfolios (Presentation, slide 17; Transcript, page 5, Soumya Chava).
Headwinds
Revenue de-growth in Laurus Bio divisionSourceBio division revenues declined 38% YoY and 17% QoQ to INR 29 cr in Q2 FY27 (INR 64 cr in H1 FY27, down 16% YoY) attributed to campaign phasing and delayed commercialization (Presentation, slide 21; Transcript, page 5, Krishna Chava).
Working capital drag and negative free cash flowSourceOperating cash flow declined 26% YoY to INR 805 cr in H1 FY27 due to higher net working capital from strategic inventories, while capex of INR 864 cr led to slightly negative free cash flow (Presentation, slide 14; Transcript, page 19, V.V. Ravi Kumar).
Stagnant API growth within Affordable MedicinesSourceAffordable Medicines API revenue was essentially flat at INR 625 cr in Q2 FY27 (up 1% YoY, down 4% QoQ) and ARV revenue grew only 0.3% YoY to INR 735 cr (Presentation, slide 17).
New businesses and products
acquisition · Definitive agreement signed on 29th October 2026 to acquire 60% stake
Galenvs Sciences Acquisition
Expected benefit
Expands position into fast-growing oligonucleotide CDMO market with early-stage oligo platform, precision magnetic nanoparticles, and North American footprint
Risks
Currently no commercial customers in oligonucleotides; execution risk in integrating Canadian R&D with Indian manufacturing
Timeline
Subject to due diligence; no specific closing timeline mentioned
Investment
USD 3.75 million total investment (pre-money valuation of USD 3.50 million, including USD 2.75 million primary infusion)
acquisition · Definitive agreement / proposed to acquire 52% stake
SI & C Resins Acquisition
Expected benefit
Secures long-term supply of critical solid support resins and chromatography stationary phases for peptide synthesis and purification, strengthening manufacturing competitiveness
Risks
Limited direct financial contribution; captive supply reliability focus
Operating cash flow decline and negative free cash flow amid aggressive capexSourceH1 operating cash flow declined 26% YoY to INR 805 cr due to inventory build-up, and free cash flow turned negative after INR 864 cr capex (Presentation, slide 14; Transcript, page 19).
Unquantified losses and delay in commercial ramp at Laurus BioSourceRevenues fell 38% YoY in Q2 to INR 29 cr, commercial supplies from LB-4 delayed to Q1 FY28, and management deflected questions regarding Laurus Bio's INR 50 cr H1 loss and breakeven offline (Presentation, slide 21; Transcript, pages 19-20).
How the call went
Substantive call detailing operational milestones in complex chemistry and peptides, offset by frequent refusals to share granular segment capex, project counts, or address specific GLP-1 queries.
Specific or vague
Management offered clear quantitative capacity figures for reactor volumes (>9,000 kL API, >16,000 L SPPS, >240 kL fermentation), but repeatedly declined to disclose financial parameters such as peptide capex, asset turn estimates, or commercial molecule counts.
Candour
Management was candid about the long lead times for peptide revenue (2029) and acknowledging negative free cash flow due to growth capex, but was guarded regarding product pipeline specifics.
The hard questions
Analysts probed deeply into peptide investments, GLP-1 contracts, Laurus Bio profitability/breakeven, and cash flows. Management answered the operational timeline and cash flow rationale but declined to answer GLP-1 involvement or Laurus Bio loss breakdown.
What analysts pressed on
Commercialization timeline, gross block investment, and expected asset turns for the 16,000 L peptide facility
Involvement in commercial or clinical GLP-1 opportunities
Negative free cash flow and inventory build-up in H1 FY27
Performance and financial losses at Laurus Bio along with the EBITDA breakeven timeframe
Customer and product concentration risks within the CDMO segment
Answers that sidestepped
Refusal to comment on whether Laurus is participating in existing GLP-1 peptide opportunities (Krishna Chava: 'We don't want to comment', Transcript, page 15).
Refusal to give gross block or asset turn estimates for the peptide block (Dr. Chava: 'beyond that, we are not going to give you how much of capex we invested, what is the asset turn ratio...', Transcript, page 13).
Deflecting the question on Laurus Bio's H1 net loss (~INR 50 cr) and EBITDA breakeven to offline IR discussions (Krishna Chava / Dr. Chava, Transcript, page 20).
Declining to state active molecule counts by clinical phase or commercial stage (Krishna Chava / Dr. Chava, Transcript, pages 12-13).
Numbers against the story
Management emphasized unprecedented momentum and record profitability (EBITDA margin up to 34.5%, sales up 33% YoY). However, the cash performance diverges: operating cash flows fell 26% YoY due to working capital expansion in inventories, and free cash flow after capex was negative. Furthermore, while the long-term peptide and bio narratives are highlighted, Bio revenues contracted by 38% YoY in Q2 and commercial revenue from the new peptide assets is guided only for ~2029.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.